ClinicalTrials.gg
RecruitingNCT05728749Updated Jul 6, 2023

A Multicentre, Prospective, Non-interventional Trial Monitoring Therapy Pathways of Asthma Patients Treated With an Extra-fine ICS/LABA/LAMA Single-inhaler Triple Therapy in a Real-world Setting and Characterizing the Effects on Health-related Outcomes

An observational study in ASTHMA, sponsored by Chiesi SAS. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-06.

Sponsored by Chiesi SAS (part of Chiesi Farmaceutici S.p.A.) · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 8 months ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Asthma by Chiesi Farmaceutici S.p.A. — 11 open to participants now, 11 under way, 2 of them phase 3. Asthma · Chiesi Farmaceutici S.p.A..

Planned enrollment
8th of 15
300 · median 300
Started
2023
with 4 others
Observational
15 of 81
6 open now
Primary completion
2024-03
later than 0 of 10 live
Registered
64th of 81
by date

Among the 81 studies in Asthma by Chiesi Farmaceutici S.p.A., this one is the 8th largest by planned enrollment of the 15 observational ones that give a count, is one of 5 that started in 2023, is one of 15 observational ones, reaches primary completion later than 0 of the 10 other live ones, and was the 64th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

11 of the 81 studies in Asthma by Chiesi Farmaceutici S.p.A. are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Asthma by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

TriMaximize, a non-interventional trial aims to collect prospective, longitudinal data from asthma patients under routine care, for whom their treating physician has decided to prescribe Trimbow® (beclometasone/formoterol/glycopyrronium).

Read the detailed description

TriMaximize, a non-interventional trial aims to collect prospective, longitudinal data from asthma patients under routine care, for whom their treating physician has decided to prescribe Trimbow® (beclometasone/formoterol/glycopyrronium).

Trimbow is a fixed triple therapy containing a long-acting muscarinic antagonist (LAMA, glycopyrronium), a long-acting beta-adrenergic agonist (LABA, formoterol) and an inhaled corticosteroid (ICS, beclometasone).

Asthma patients often need to use multiple inhalers as part of their therapy, which require different inhalation techniques. It has been shown that the use of several inhalers of different mode of action, design and dosage requirements may have a detrimental effect on patient adherence and subsequent treatment outcomes.

In this prospective, non-interventional trial, the investigators aim to evaluate aspects of adherence to Trimbow, a single-inhaler triple therapy (SITT) as a maintenance treatment of asthma, to gather knowledge from routine care on whether appropriate step-up to SITT leads to greater adherence and better health outcomes.

03

Conditions studied

  • ASTHMA

Browse trials for

Keywords

  • ASTHMA
  • TRIMBOW
  • TRIPLE THERAPY
  • BECLOMETHASONE
  • FORMOTEROL
  • GLYCOPYRRONIUM
  • TRIMAXIMIZE
  • REAL-WORLD SETTING
  • EXTRAFINE
  • SINGLE-INHALER
  • COHORT
  • PROSPECTIVE
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients will only be included in the Non-Interventional Trial if Trimbow® has been prescribed in line with its current marketing authorisation and the guidance specified in the summary of product characteristics (SmPC).

Physicians are urged to offer enrolment to all of their eligible patients consecutively as they present for their routine visit, and not select patients from their patient database.

Eligible patients may only be included in the NIT after providing written (witnessed, where required by law or regulation), IEC-approved informed consent.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients ≥ 18 years of age,
  • Patients with confirmed leading diagnosis of asthma with or without concomitant ,
  • Physician decision to start fixed triple therapy with ICS/LABA/LAMA (Trimbow® MS or HS) according to its current authorised indication. The treatment decision must be made independently from participation in this NIS,
  • Patients willing and able to sign an for use of their pseudonymised clinical data within the present non-interventional study,
  • Patient must be covered by a social security scheme,
  • Patient must be treated by one of the practitioners of the centre (at office or at hospital).

Exclusion criteria

Exclusion Criteria:

  • Participation in an interventional clinical trial within 30 days prior to enrolment into the present non-interventional study or planned enrolment in an interventional clinical trial during the observational period.
  • Patients unable to understand scope of study or patients unwilling to participate in study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Asthma patients

    Trimbow pMDI prescribed for maintenance treatment of adult asthma as per the licensed indication.

    Other: Non-interventional

Interventions

  • OtherNon-interventional

    As this is a non-interventional trial, only data obtained within the current routine management of asthma at outpatient respiratory centres or GP centres will be documented.

06

What researchers measure

Primary outcomes

  1. To describe patient characteristics and therapy pathways for patients with a diagnosis of moderate to severe asthma who are treated with Trimbow in real world practice

    Descriptive analysis of patient demographics.

    Time frame: 12 months

Secondary outcomes

  1. Assess asthma control (ACT)

    Change from baseline in ACT scores.

    Time frame: 12 months

  2. Assess quality of life

    Change from baseline in Mini-AQLQ scores.

    Time frame: 12 months

  3. Assess treatment adherence

    Change from baseline in TAI scores.

    Time frame: 12 months

  4. Analyse parameters of lung function using spirometry

    Change from baseline in FEV1.

    Time frame: 12 months

  5. Analyse parameters of small airways disease

    Change from baseline in small airway function measured by pre-dose AUCAX (Area under the curve of reactance) using available oscillometry system.

    Time frame: 12 months

  6. Analyse parameters of asthma-related airway inflammation

    Change from baseline in percentage of patients with a fraction of exhaled nitric oxide (FeNO) below or above 20 ppb.

    Time frame: 12 months

  7. Analyse parameters of persistent airflow limitation

    Change from baseline in percentage of patients with persistent airflow limitation (PAL); PAL defined as post-BD FEV1 \<80% predicted and post-BD FEV1/FVC Ratio \< 0.7.

    Time frame: 12 months

  8. Analyse the incidence of asthma exacerbations

    Number of exacerbations 12 months prior to baseline and during study.

    Time frame: 12 months

  9. Analyse the severity of asthma exacerbations as defined by the American Thoracic Society/European Respiratory Society (ATS/ERS) classification of asthma exacerbations

    Severity of exacerbations, defined according to the ATS/ERS classification of asthma exacerbations, will be analysed 12 months prior to baseline and during study.

    Time frame: 12 months

  10. Analyse use of rescue medication

    Use of any rescue medication 7 days prior to baseline and during study 7 days prior to respective visit.

    Time frame: 12 months

  11. Analyse use of systemic corticosteroids

    Use of any systemic corticosteroids 12 months prior to baseline and during study.

    Time frame: 12 months

  12. Assess adverse events associated with use of Trimbow

    Assessment of the number and type of adverse events.

    Time frame: 12 months

  13. Assess retention rate with Trimbow

    Assess continuation of treatment with Trimbow (retention rate of Trimbow) at month 12.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • ChiesiFrance
    Bois-Colombes, 92270, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Mar 2024, 12 months after the start.

Of 90 industry-sponsored observational studies under Asthma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 58. This study's planned 12 months is below that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2023
First posted
Feb 15, 2023
StartActual
Mar 3, 2023
Primary completionEst.
Mar 2024
CompletionEst.
Mar 2025
Last update
Jul 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05728749
Lead sponsor
Chiesi SAS
Collaborators
Gesellschaft für Therapieforschung mbH
Responsible party
Sponsor
First posted
Feb 15, 2023
Start date
Mar 3, 2023
Primary completion
Mar 2024 (estimated)
Completion
Mar 2025 (estimated)
Last update
Jul 6, 2023

Study contacts

Christine CONTRE, Dr
Contact
c.contre@chiesi.com
+33675085149
Justine FIOCCA, Pharm.D
Contact
j.fiocca@chiesi.com
+33785823381
Arnaud BOURDIN, Pr
principal investigator · University Hospital, Montpellier

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion